Research ArticleArticle
Open Access
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller and Janet E. Pope
The Journal of Rheumatology December 2017, jrheum.161539; DOI: https://doi.org/10.3899/jrheum.161539
Alan Kivitz
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Ewa Olech
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Michael A. Borofsky
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Beatriz Zazueta
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Federico Navarro-Sarabia
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Sebastião C. Radominski
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Joan T. Merrill
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
César Pacheco-Tena
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Jinglan Pei
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Clare Nasmyth-Miller
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
Janet E. Pope
From the Altoona Center for Clinical Research, Duncansville, Pennsylvania; University of Nevada School of Medicine, Las Vegas, Nevada; Clinical Research Center of Reading, Reading, Pennsylvania; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genentech, South San Francisco, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Baja California, Mexico; Hospital Virgen Macarena, Servicio de Reumatología, Sevilla, Spain; Universidade Federal do Paraná, Curitiba, Brazil; Roche Pharmaceuticals, Welwyn Garden City, London, UK; St. Joseph’s Health Centre, Western University, London, Ontario, Canada. This study was funded by Genentech, a member of the Roche Group, and Hoffmann-La Roche. Genentech and Hoffmann-La Roche sponsored the study and participated in the design of the study, as well as in the collection, analysis, and interpretation of the data. A. Kivitz received consulting fees and speakers bureau fees from Genentech. E. Olech received research grants and consulting fees from Genentech. F. Navarro-Sarabia received consulting fees and speakers bureau fees from Roche Pharmaceuticals. S.C. Radominski received research grants from Roche Pharmaceuticals. J.T. Merrill received consulting fees from Roche Pharmaceuticals and Genentech. J. Pei is an employee of Genentech. C. Nasmyth-Miller is an employee of Roche Pharmaceuticals. A. Kivitz, MD, Altoona Center for Clinical Research; E. Olech, MD, University of Nevada School of Medicine; M.A. Borofsky, MD, Clinical Research Center of Reading; B. Zazueta, MD, Centro de Investigacion en Enfermedades Reumaticas; F. Navarro-Sarabia, MD, Hospital Virgen Macarena, Servicio de Reumatología; S.C. Radominski, MD, Universidade Federal do Paraná; J.T. Merrill, MD, Oklahoma Medical Research Foundation; C. Pacheco-Tena, MD, Universidad Autónoma de Chihuahua; J. Pei, BS, Genentech; C. Nasmyth-Miller, DPhil, Roche Pharmaceuticals; J.E. Pope, MD, St. Joseph’s Health Centre, Western University. Address correspondence to Dr. A. Kivitz, Altoona Arthritis and Osteoporosis Center, 175 Meadowbrook Lane, PO Box 909, Duncansville, Pennsylvania 16635, USA. E-mail: ajkivitz@yahoo.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 19, 2017.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E. Pope
The Journal of Rheumatology Dec 2017, jrheum.161539; DOI: 10.3899/jrheum.161539
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C. Radominski, Joan T. Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E. Pope
The Journal of Rheumatology Dec 2017, jrheum.161539; DOI: 10.3899/jrheum.161539